Mechanism of Action
NPR-A Activation and cGMP Signaling
ANP binds NPR-A (guanylyl cyclase A receptor, identical target as nesiritide) on vascular smooth muscle, renal tubular cells, and adrenal cells. Receptor-intrinsic guanylyl cyclase raises intracellular cGMP, activating PKG. Renal effects: inhibits sodium reabsorption in collecting ducts, inner medullary collecting duct, and proximal tubule -- producing natriuresis and secondary diuresis. Vascular: smooth muscle relaxation via PKG-mediated phosphatase activation, causing vasodilation.
RAAS Suppression
ANP suppresses the renin-angiotensin-aldosterone axis at multiple levels: inhibits renin secretion from juxtaglomerular cells, reduces adrenal aldosterone synthesis, and opposes angiotensin II vasoconstriction. This comprehensive RAAS suppression provides prolonged antihypertensive and volume-reducing effects beyond the direct natriuretic/vasodilatory effects.
Research Summary
ADHF Treatment (Japan)
Approved (Japan)Carperitide (alpha-ANP) approved in Japan 1995 for ADHF treatment. Widely used in Japanese critical care settings for pulmonary congestion, reducing PCWP, improving symptoms, and producing natriuresis. Japanese registry data show favorable outcomes with carperitide-based regimens. Not pursued to FDA approval largely due to nesiritide (BNP) entering US development first and the ASCEND-HF regulatory landscape.
Hypertension and Obesity
Active ResearchGenetic variants reducing ANP/BNP levels associate with salt-sensitive hypertension and obesity. ANP promotes lipolysis in adipose tissue via NPR-A/cGMP/PKG pathway -- elevated ANP levels in lean subjects may contribute to adipose mobilization during stress. Low natriuretic peptide levels in obesity are paradoxical (obesity-related suppression of ANP/BNP despite elevated filling pressures) and may worsen cardiometabolic risk.
Calculate your Atrial Natriuretic Peptide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| ADHF (carperitide, Japan) | 0.025-0.1 mcg/kg/min IV continuous infusion | Continuous infusion during hospitalization | Intravenous |
| Hemodynamic/renal research | 1-4 pmol/kg/min IV infusion in human physiological studies | Per session | Intravenous |
Very short half-life necessitates continuous infusion. Blood pressure monitoring required. Carperitide not available in the US; nesiritide is the comparable FDA-approved agent.
Interactions
Safety Profile
Hypotension is the primary adverse effect and dose-limiting factor. Excessive diuresis causing hypovolemia and reflex tachycardia at high doses. No significant cardiac arrhythmias or direct organ toxicity. Carperitide Japanese registry: favorable tolerability at recommended doses. The ultra-short plasma half-life (~2 min) provides rapid reversibility if hypotension occurs. Monitor serum electrolytes during infusion (hyponatremia possible with excessive natriuresis). Not appropriate without hemodynamic monitoring capability.
References
- [1]de Bold AJ, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89-94.
- [2]Hayashi M, et al. Carperitide as a first-line diuretic agent in patients with acute heart failure. Heart Vessels. 2012;27(6):579-585.